Lilly sets up $50 million venture fund for medtech:
This article was originally published in Clinica
Executive Summary
A new venture capital fund targeting medical technology companies has been established by Eli Lilly. The Indianapolis, Indiana-based pharmaceutical group is seeking to invest $50m in placements of up to $5m. Its focus is a broad one: companies developing emerging and innovative technologies in the fields of diagnostics and therapeutic devices, as well as products combining pharmaceuticals, medical devices and/or diagnostics. Although Lilly has expertise in drug delivery, it is no longer the medtech heavyweight it once was. In the mid-1990s it decided to focus on pharmaceuticals, setting up Guidant to accommodate its medical device activities and divesting other non-pharma assets separately.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.